Analyst Rating Update on Catalent (CTLT)

Catalent (NYSE:CTLT) : 9 analysts are covering Catalent (NYSE:CTLT) and their average rating on the stock is 2.11, which is read as a Buy. 4 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 5, which recommends a Strong Sell affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Catalent (NYSE:CTLT) : The consensus price target for Catalent (NYSE:CTLT) is $27.9 for the short term with a standard deviation of $2.41. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $31, however, the pessimist price target for the company is $25.

For the current week, the company shares have a recommendation consensus of Buy. Also, Wells Fargo upgrades its view on Catalent (NYSE:CTLT) according to the research report released by the firm to its investors. The shares have now been rated Outperform by the stock experts at the ratings house. Earlier, the shares had a rating of Market Perform. The rating by the firm was issued on June 21, 2016.

Catalent (NYSE:CTLT): stock turned positive on Tuesday. Though the stock opened at $21.31, the bulls momentum made the stock top out at $22.18 level for the day. The stock recorded a low of $21.3 and closed the trading day at $22.13, in the green by 3.95%. The total traded volume for the day was 1,380,035. The stock had closed at $21.29 in the previous days trading.

In an insider trading activity,The officer (See Remarks) of Catalent, Inc., Walsh Matthew M sold 21,197 shares at $28.85 on May 27, 2016. The Insider selling transaction had a total value worth of $611,533. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Catalent, Inc. is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Companys segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecules lifecycle. The Medication Delivery Solutions segment provides formulation, development and manufacturing services for delivery of drugs and biologics, administered through injection, inhalation and ophthalmic routes, using both traditional and advanced technologies. The Development and Clinical Services segment provides manufacturing, packaging, storage and inventory management for drugs and biologics in clinical trials.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *